Results 301 to 310 of about 155,463 (366)

AOSNP‐ADAPTR resource level‐based recommendations on practical diagnostic strategies for WHO CNS5 adult‐type diffuse gliomas

Brain Pathology, EarlyView.
ADAPTR recommendations for Adult‐type Diffuse Gliomas in Resource‐restrained settings. Abstract The fifth edition of the WHO classification of CNS Tumors (WHO CNS5) has revised the diagnostic and grading criteria for Adult‐type Diffuse Gliomas (ADGs) by integrating molecular parameters with histologic features.
Vani Santosh, Chitra Sarkar, Shilpa Rao, Ho‐Keung Ng, Junji Shibahara, Maysa Al‐Hussaini, Michael E. Buckland, Sung‐Hye Park, Tarik Tihan, Pieter Wesseling, David N. Louis, Takashi Komori   +11 more
wiley   +1 more source

Sarcoidosis misdiagnosed as pulmonary malignancy: a case report. [PDF]

Front Oncol
Zhang H, Huang Y, Zhao X, Fan D, Xing Z, Sun X, Zhu L.   +6 more
europepmc   +1 more source

The impact of Foxp3+ regulatory T‐cells on CD8+ T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley   +1 more source

A case of GLI1-altered mesenchymal pleural tumour with novel gene fusion: a clinical perspective. [PDF]

J Surg Case Rep
Bahajjaj SIBZ, Chia CML, Farah BL.
europepmc   +1 more source

Third‐Generation EGFR‐TKIs Combined With Chemotherapy in Advanced Non‐Small Cell Lung Cancer: A Real‐World Study

Cancer Science, EarlyView.
This study was the largest sample size of first‐line third‐generation TKIs combined chemotherapy among advanced EGFRm NSCLC patients in the real world. It was never reported that aumolertinib and furmonertinib showed comparable PFS benefits to osimertinib in combination with chemotherapy. The overall safety profile remained acceptable. ABSTRACT FLAURA2
YuQin Jiang, Qi Liang, Yuting Zhu, Xiao Liang, Ruohan Huang, Wenxin Zhou, Chen Zhang, Jun Li, Jiali Xu, Renhua Guo   +9 more
wiley   +1 more source

A New WHO Entity of SMARCB1/INI1-Deficient Undifferentiated Thoracic Tumors: Rare, Aggressive, and Overlooked. [PDF]

Cureus
Bekhakh C, Haloui A, Bakhti M, Karich N, Bennani A.   +4 more
europepmc   +1 more source

A Transcriptomic Analysis of Cancer‐Stromal Interactome in Lung Cancer Xenograft Models

Cancer Science, EarlyView.
We conducted a comprehensive analysis of the lung cancer interactome to identify key ligand–receptor pairs involved in the aggressiveness of lung adenocarcinoma. Tumor necrosis factor superfamily member 12 and its receptor tumor necrosis factor receptor superfamily member 12A signaling axis may be potential candidates for therapeutic intervention for ...
Yuriko Takayama‐Isagawa, Daisuke Komura, Takayuki Isagawa, Yusuke Amano, Atsushi Kihara, Tamaki Miura, Taichiro Yoshimoto, Hiroyoshi Tsubochi, Kazutaka Fujita, Koichi Hagiwara, Makoto Maemondo, Tetsuo Ushiku, Shumpei Ishikawa, Noriyoshi Fukushima, Kentaro Inamura, Daisuke Matsubara, Toshiro Niki   +16 more
wiley   +1 more source

A retrospective evaluation of risk factors for an inadequate surgical margin in preoperative lipiodol marking for small-sized pulmonary lesions. [PDF]

J Thorac Dis
Takeda S, Fumimoto S, Okai S, Shindo Y, Toyohara K, Sato K, Hanaoka N, Katsumata T.   +7 more
europepmc   +1 more source

Prognostic value of pulmonary vessel-related structures in rapid progression of idiopathic inflammatory myopathy-associated interstitial lung disease: a retrospective study from two centres. [PDF]

BMJ Open Respir Res
Qiang Y, Wang H, Yang X, Ni Y, Wang J, Liu A, Du J, Xi L, Hu Y, Ren Y, Xie B, Wang S, Zhu L, Geng J, Liu M, Dai H.   +15 more
europepmc   +1 more source

Intrapulmonary lymph nodes. [PDF]

J Bras Pneumol
Marchiori E, Hochhegger B, Zanetti G.
europepmc   +1 more source